The Danish biotech company Bavarian Nordic is part of a co-operation aimed at developing an Ebola vaccine as quickly as possible.
As well as Bavarian Nordic, the co-operation includes the US National Institute of Allergy and Infectious Diseases (NIAID), part of the American National Institutes of Health (NIH), and the US medicinal and pharmaceutical giant Johnson & Johnson.
“Given the current global health crisis affecting West Africa and beyond, there is a clear need for efficacious protection and treatment against highly lethal infections like Ebola,” Paul Chaplin, the president and CEO of Bavarian Nordic said in a press release.
“In our contribution to the development of a potential new Ebola vaccine, we leverage our expertise in the development and manufacturing of smallpox vaccines, which we have supplied to the US Government since 2010.”
The Ebola outbreak has gathered momentum over the past weeks and has now claimed over 2,000 lives in west Africa.
Bavarian Nordic and its partners are expecting to be able to hold initial human trials of the vaccine sometime in 2015.
Just last week, the company revealed that it was currently testing a new Ebola vaccine on apes and wouldn’t be averse to rushing trials should the World Health Organisation come calling.